Global TB Strategy Questioned as Landmark Study Reveals Millions of Misdiagnoses

NEW YORK – Tuberculosis, the world's deadliest infectious disease, may be systematically misdiagnosed on a massive scale, according to a groundbreaking study that carries profound implications for global health funding, resource allocation, and patient survival. The research suggests that annually, millions of people are either incorrectly told they have TB, while a different, potentially fatal illness goes untreated, or are wrongly cleared of the disease, allowing it to spread unchecked.

This new analysis, published in Nature Medicine, casts a stark light on the diagnostic challenges plaguing the fight against an illness that claimed 1.23 million lives in 2024 and infects approximately 10 million people each year. The findings challenge the accuracy of official statistics and force a difficult conversation about the efficacy of current public health strategies in low- and middle-income countries.

The Scale of the Diagnostic Crisis

The study, co-authored by Nicolas Menzies, an associate professor of global health at the Harvard T.H. Chan School of Public Health, analyzed 2023 data from 111 countries. By developing a formula to estimate diagnostic errors submitted to the World Health Organization (WHO), the researchers uncovered a startling discrepancy between reported cases and the likely reality on the ground.

• False Positives: The most significant finding was the scale of over-diagnosis. The study estimates that 2 million or more individuals each year are told they have TB and begin treatment, when in fact they suffer from a different condition.
• False Negatives: Conversely, the model indicates that approximately 1 million people with active TB are missed by the healthcare system annually after seeking care for their symptoms. These individuals receive a false-negative diagnosis, or no diagnosis at all.
• The Bottom Line: "Amongst all of those individuals who are diagnosed and treated for TB every year, perhaps a quarter of them — and maybe even higher — might not have TB disease," Menzies stated, calling the issue a long-standing "blind spot" in the global TB response.

The Root of the Errors: Technology vs. Judgment

The high rate of misdiagnosis stems from a combination of imperfect diagnostic tools and the difficult realities of frontline healthcare. While modern molecular tests offer high accuracy, their availability remains limited in many regions.

A significant portion of diagnoses are therefore made clinically—based on a practitioner's assessment of symptoms like a persistent cough, weight loss, and night sweats.

• Diagnostic Limitations: Traditional methods, such as examining a sputum sample under a microscope, have variable accuracy. Newer PCR-based machine analysis is far superior but not universally accessible.
• The Clinical Guess: Well over a third of all TB diagnoses in low- and middle-income countries are made without a positive laboratory test. Menzies and his team believe this reliance on clinical judgment, while well-intentioned, is the primary driver of the high false-positive rate.
• A Generational Lag: Dr. Marcel Behr, a professor at McGill University and founding director of its International TB Centre, theorizes that many clinicians "grew up in an era where there were not good TB diagnostics" and are accustomed to trusting their gut instinct over test results, even when improved technologies are available.

A Divided Expert Response

The study's conclusions have been met with both praise for highlighting a critical issue and concern over potential unintended consequences, particularly regarding funding and clinical confidence.

Support for Scrutiny: Dr. Behr lauded the research for its "rigorous approach" and for bringing a much-needed focus to an understudied problem. "The issue about whether we have false positives has been understudied," he noted, emphasizing the importance of understanding the full scope of diagnostic accuracy.

Fears of Backlash: Dr. Lucica Ditiu, head of the Stop TB Partnership, expressed deep concern that the findings could be misinterpreted.

• Risk to Funding: She worries the study could cast doubt on the reliability of TB statistics, potentially prompting governments and international donors to divert crucial funds away from TB programs.
• Clinical Hesitancy: Ditiu also fears the focus on misdiagnosis could make frontline clinicians, especially those in under-resourced settings, reluctant to make a diagnosis for fear of being wrong. "If it is to say: Oh my goodness, clinical diagnosis is so bad, then this is very damaging," she warned.

The High Stakes of Getting It Wrong

The human and public health consequences of misdiagnosis are severe, creating two distinct but equally dangerous scenarios.

• The Peril of a False Positive: Patients wrongly diagnosed with TB undergo a months-long, often arduous treatment regimen with potentially toxic drugs. More critically, their actual illness—which could be lung cancer, severe pneumonia, or chronic obstructive pulmonary disease (COPD)—goes undiagnosed and untreated, often until it is too late.
• The Peril of a False Negative: When a person with active TB is told they are clear, two tragedies unfold. First, their own health deteriorates as the disease progresses untreated. Second, they remain infectious, continuing to spread the airborne bacteria within their family and community, fueling the broader epidemic.

The Path Forward: A Call for Better Tools

Despite the debate, there is consensus on one point: the world needs better, faster, and more accessible diagnostic tools to fight tuberculosis effectively.

Dr. Ditiu emphasized that the study's ultimate impact should be a catalyst for innovation. "If the purpose of the paper is to say that we need better tools, better diagnostics — that, I think, is spot on," she said. She argues that the primary crisis remains the "huge number of people that are not diagnosed, at all, in any shape or form."

The study by Menzies and his colleagues does not suggest abandoning clinical judgment, which remains a vital tool in remote and underfunded areas. Instead, it serves as a powerful data-driven call to action. The global health community now faces the challenge of investing in and deploying superior diagnostic technologies, while simultaneously supporting and training clinicians to use them effectively. The accuracy of the world's response to its top infectious killer depends on it.